{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"DLTs will be determined for each subject as a binary variable indicating whether or not the subject experienced a DLT during Cycle 1","groups":[{"description":"Cohort 1) 5mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG000","title":"Phase I 5 mg Ruxolitinib"},{"description":"Cohort 2) 10mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG001","title":"Phase I 10 mg Ruxolitinib"},{"description":"Cohort 3) 15mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG002","title":"Phase I 15 mg Ruxolitinib"}],"paramType":"NUMBER","populationDescription":"Participants who are DLT evaluable","reportingStatus":"POSTED","timeFrame":"28 days","title":"Dose Limiting Toxicity (DLT)","type":"PRIMARY","unitOfMeasure":"participants"}